secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-028373
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q4 net loss $128.9M; cuts workforce 27%, ends NTLA-3001
----------------------------------------------------------------

- Q4 2024 net loss $128.9M vs $132.2M prior year; revenue $12.9M.
- Ended 2024 with $861.7M cash; funding into first half of 2027.
- Workforce reduction of ~27% in 2025; expects $8M severance charges.
- Phase 3 HAELO (NTLA-2002) dosed first patient; BLA submission planned H2 2026.
- Enrollment in MAGNITUDE (nex-z for ATTR-CM) ahead of projections, >550 patients by year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025028373/0000950170-25-028373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025028373/ntla-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-028373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer